Fetus-Placenta-NewbornLocalization of p43 placental isoferritin in human maternal-fetal tissue interface*,**
Section snippets
Samples
Villous tissue and decidua were collected from 40 healthy pregnant women undergoing elective termination of a normal pregnancy between 5 and 20 weeks’ gestation and from 10 pregnant women at term, 5 at elective cesarean delivery and 5 after normal vaginal delivery. All pregnancies were uncomplicated with the fetal heart rate within normal range. Gestational age was determined from the menstrual history and confirmed by an ultrasonographic scan. Villous and decidual tissues were separated by
Results
First-trimester placental tissue exhibited positive immunostaining of p43 that was uniformly and consistently localized in the syncytiotrophoblast and Hofbauer cells within different types of villi, including stem (Fig 1, A and B ) and anchoring (Fig 1, C ) villi.
Comment
There was expression of p43 on both sides of the maternal-fetal tissue interface. Immunoreactivity was observed in the syncytiotrophoblast layer and Hofbauer cells, as well as in the population of macrophages in the maternal decidua. Likewise, expressions of other cytokines by the trophoblast and other cells in the normal placenta have been previously reported.13 Inflammatory cytokines such as interleukin 1, tumor necrosis factor α, and interleukin 6 were immunolocalized to the
References (25)
Lymphohematopoietic cytokines in the female reproductive tract
Curr Opin Immunol
(1991)- et al.
Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?
Immunol Today
(1993) - et al.
Preparation and characterization of monoclonal antibodies specific to placental ferritin
Clin Chem
(1985) - et al.
Activated lymphocytes from breast cancer patients express the characteristics of type 2 helper cells: a possible role for breast cancer-associated p43
Cancer Lett
(1998) - et al.
Differential distribution of interleukin-1α and interleukin-1β proteins in human placentas
J Reprod Immunol
(1992) - et al.
The role of cytokines in gestation
Crit Rev Immunol
(1994) - et al.
Placental isoferritin as a physiological down regulator of cellular immunoreactivity during pregnancy
Clin Exp Immunol
(1989) - et al.
A unique subunit of placental ferritin identified by the use of monoclonal antibodies
Ital J Clin Pathol
(1986) - et al.
Ferritin as a marker of malignancy
- et al.
Isoferritins in HIV infection: relation to clinical stage CD8 lymphocyte binding and the pathogenesis of AIDS
AIDS
(1989)
Immune dysregulation in Ethiopian immigrants in Israel: relevance to helminth infections?
Clin Exp Immunol
Immunohistochemistry
Cited by (18)
Materno-fetal iron transfer and the emerging role of ferroptosis pathways
2022, Biochemical PharmacologyThe Novel C24D Synthetic Polypeptide Inhibits Binding of Placenta Immunosuppressive Ferritin to Human T Cells and Elicits Anti-Breast Cancer Immunity In Vitro and In Vivo
2014, Neoplasia (United States)Citation Excerpt :During normal pregnancy, PLIF expression is elevated as early as day 11, remains elevated throughout gestation, and declines at term. PLIF is low in missed abortions, early pregnancy failures, and intrauterine growth restriction [10,15–18]. Furthermore, it is a physiological down-regulator of cell-mediated immune reactivity during pregnancy [19,20].
Regulation of ferritin genes and protein
2002, BloodCitation Excerpt :However, subsequent evaluations of ferritin levels in tumor tissue itself have revealed a complex, perhaps disease-specific picture: for example, in some cases such as colon cancer,175 testicular seminoma,176 and breast cancer,177,178 increases in ferritin in tumor tissue versus comparable normal tissue have been reported; in other cases, including liver cancer, a decrease in ferritin is seen.179 New forms of ferritin may be involved in certain situations: Moroz and coworkers have described a novel isoform of ferritin that is elevated in the serum of patients with neoplastic breast disease as well as during pregnancy and HIV infection.180-182 Molecular explanations for the perturbations of ferritin in cancer have been slow to advance, with often conflicting conclusions.
- *
Supported by a research grant from Women First Health Care. R.M. was supported by a grant from the British Council.
- **
Reprint requests: Ron Maymon, MD, Department of Obstetrics and Gynecology, Assaf Harofe Medical Center, affiliated to the Tel Aviv University, Zerifin 70300, Israel.